medigraphic.com
ISSN 1561-2937 (Print)

2015, Number 3

Next >>

Rev Cubana Cardiol Cir Cardiovasc 2015; 21 (3)

SPRINT and the redefining of blood-pressure target. Yes, maybe or not?

Morales SA

Language: Spanish
References: 16
Page: 130-132
PDF size: 403.35 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet.2002; 360(9349):1903-13.

  2. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and downthe J-shaped curve. Eur Heart J. 2010; 31(23):2837–40.

  3. Tsika EP, Poulimenos LE, Boudoulas KD, Manolis AJ. The J-Curve in Arterial Hypertension: Fact or Fallacy? Cardiology. 2014; 129(2):126–35.

  4. Morales Salinas, Coca A. Obesidad, actividad física y riesgo cardiovascular: clasificación ergo-antropométrica, variables farmacológicas, biomarcadores y ―paradoja del obeso‖. Med Clin(Barc).2010;134(11):492–8.

  5. Morales-Salinas A, Wyss F, Coca A, Ramírez AJ, Valdez O, Valerio LF. Divergencias entre guías de 2013 y 2014 de la hipertensión arterial. Posición de la Sociedad Centroamericana y del Caribe de Hipertensión y Prevención Cardiovascular. Rev Panam Salud Pública. 2015; 37(3):172–8.

  6. Cushman WC, Whelton PK, Fine LJ, Wright JT, Reboussin DM, Johnson KC, Oparil S. SPRINT Trial Results. Latest News in Hypertension Management. Hypertension. DOI: 10.1161/HYPERTENSIONAHA.115.06722.

  7. Morales Salinas A, Cañedo Andalia R, González Díaz A. Algunas consideraciones sobre el factor de impacto y la visibilidad internacional de la producción científica cubana en ciencias médicas. Rev Cubana Cardiol Cir Cardiovasc. 2011; 17(3):201-08.

  8. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. DOI: 10.1056/NEJMoa1511939.

  9. Drazen JM, Morrissey S, Campion EW, Jarcho JA. A SPRINT to the Finish. N Engl J Med. DOI: 10.1056/NEJMe1513991

  10. Perkovic V, Rodgers A. Redefining Blood-Pressure Targets — SPRINT Starts the Marathon. N Engl J Med. DOI: 10.1056/NEJMe1513301

  11. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-72.

  12. Chobanian AV. Time to Reassess Blood-Pressure Goals. N Engl J Med. DOI: 10.1056/NEJMp1513290

  13. Jones DW, Weatherly L, Hall JE. SPRINT What Remains Unanswered and Where Do We Go From Here? Hypertension. DOI: 10.1161/HYPERTENSIONAHA.115.06723

  14. Esler M. SPRINT, or False Start, Toward a Lower Universal-Treated Blood Pressure Target in Hypertension. Hypertension. DOI: 10.1161/HYPERTENSIONAHA.115.06735

  15. Morales Salinas A, Coca A, Wyss F. Guidelines for Managing High Blood Pressure JAMA. 2014; 312(3):293-4.

  16. Morales-Salinas A. Atenolol in uncomplicated hypertension: Time for changes. Lancet Neurol. 2010; 9(7):65




2020     |     www.medigraphic.com